Stablecoin Development Corp (SDEV) revenue by segment
SDEVNYSEFinance ServicesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3080% below fair value
$0.78−0.00 (-0.57%)
Close on Nov 13, 2026Market cap $57.03MP/E –Yield 512.82%
Stablecoin Development Corp revenue by segment
By business segment
| Revenue | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2014 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Optical and Wound Care | – | $11.17M | $10.24M | $9.56M | – | – | – | – | – | – | – | – |
| Skin Care | – | $3.55M | $4.17M | $649.00K | – | – | – | – | – | – | – | – |
| Ophthalmology | – | – | – | – | – | – | – | – | – | $329.00K | – | – |
| Wound Care | – | – | – | – | – | – | – | – | – | $471.00K | – | – |
| Dermatology | – | – | – | – | – | – | – | – | – | $5.00K | – | – |
| Other Segments | – | – | – | – | – | – | – | – | – | $249.00K | – | – |
| Operating income | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2014 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Optical and Wound Care | – | -$3.65M | -$5.65M | -$8.68M | – | – | – | – | – | – | – |
| Skin Care | – | -$3.95M | -$8.77M | -$180.00K | – | – | – | – | – | – | – |
| Ophthalmology | – | – | – | – | – | – | – | – | – | -$7.95M | – |
| Wound Care | – | – | – | – | – | – | – | – | – | -$4.52M | – |
| Dermatology | – | – | – | – | – | – | – | – | – | -$1.33M | – |
| Urology | – | – | – | – | – | – | – | – | – | -$2.30M | – |
| Other Segments | – | – | – | – | – | – | – | – | – | -$776.00K | – |
By product or service
| Revenue | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2014 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | $9.75M | $10.46M | $14.37M | $10.18M | $9.92M | $6.56M | $12.47M | $18.13M | $11.62M | – | 99.7% | -6.8% |
| Total Product Revenue | $9.75M | $10.46M | $14.37M | $10.18M | $9.92M | $6.56M | $12.47M | – | – | – | 99.7% | -6.8% |
| Avenova Spray | $8.67M | $7.81M | $7.65M | $8.57M | $5.97M | $6.35M | – | – | – | – | 88.7% | +11.1% |
| Avenova Product | $7.20M | $6.10M | $6.50M | – | $5.97M | $6.35M | $12.31M | – | – | – | 73.6% | +18.0% |
| Other Products | $1.07M | $1.27M | $1.59M | $598.00K | $294.00K | $0 | – | – | – | – | 11.0% | -15.6% |
| Product and Service, Other | $34.00K | $0 | $30.00K | $24.00K | $18.00K | $43.00K | $34.00K | $103.00K | $280.00K | – | 0.3% | – |
| NeutroPhase | $0 | $1.38M | $976.00K | $368.00K | $524.00K | $209.00K | $169.00K | – | – | – | 0.0% | -100.0% |
| Avenova Direct | – | – | $6.50M | $6.60M | $3.30M | $1.00M | – | – | – | – | – | – |
| DERMAdoctor | – | $3.55M | $4.16M | $649.00K | $0 | $0 | – | – | – | – | – | – |
| KN95 Masks | – | – | – | $0 | $3.12M | $0 | $0 | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Stablecoin Development's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes. The KPIs tab shows these segments next to Stablecoin Development's operating metrics, with full history, charts and a link to each filing.
See a number that looks wrong?